Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Expenses data on file, last reported at $44.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $44.2 million, up 63.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.2 million (up 52.8% YoY), and the FY2025 annual result was $125.1 million, up 50.62% from the prior year.
• Operating Expenses climbed to $44.2 million in Q1 2026 per RAPP's latest filing, from $38.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $44.2 million in Q1 2026 and troughed at $6.6 million in Q2 2023.
• A 4-year average of $23.6 million and a median of $22.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 213.73% in 2024, then soared 38.57% in 2025.
• A 4-year view of Operating Expenses shows it stood at $14.8 million in 2023, then surged by 58.99% to $23.5 million in 2024, then jumped by 63.72% to $38.5 million in 2025, then increased by 14.82% to $44.2 million in 2026.
• Business Quant data shows RAPP's Operating Expenses at $44.2 million in Q1 2026, $38.5 million in Q4 2025, and $30.0 million in Q3 2025.